Correction to: Nature Cancer https://doi.org/10.1038/s43018-022-00450-6, published online 25 November 2022.
In the version of this article initially published, the Competing interests section was missing the disclosure “A.J. has research support from NCI R01CA149456, R01DE024371, and P50CA261605; and stock/options ownership in Suvica and Champions Oncology. A.J.’s institution has contracts with Cantargia, DebioPharm, Genentech, Iovance, Khar Biopharma, Merck, Moderna, Pfizer, Sanofi, and SQZ for trials where A.J. is the local P.I.” The error has been corrected in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Darragh, L.B., Knitz, M.M., Hu, J. et al. Author Correction: A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC. Nat Cancer 4, 148 (2023). https://doi.org/10.1038/s43018-022-00507-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-022-00507-6
